Fate Therapeutics Inc宣布,其候选产品FT839的新药临床试验申请已获得美国食品药品监督管理局的批准。这一进展标志着该产品向临床开发阶段迈出了关键一步。
Fate Therapeutics Inc宣布,其候选产品FT839的新药临床试验申请已获得美国食品药品监督管理局的批准。这一进展标志着该产品向临床开发阶段迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.